Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $2.20 billion. The enterprise value is $1.39 billion.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, before market open.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AKRO has 69.43 million shares outstanding. The number of shares has increased by 30.11% in one year.
| Shares Outstanding | 69.43M |
| Shares Change (YoY) | +30.11% |
| Shares Change (QoQ) | +16.61% |
| Owned by Insiders (%) | 1.75% |
| Owned by Institutions (%) | 91.14% |
| Float | 55.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.75 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.89, with a Debt / Equity ratio of 0.05.
| Current Ratio | 24.89 |
| Quick Ratio | 24.39 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.44 |
Financial Efficiency
Return on equity (ROE) is -28.87% and return on invested capital (ROIC) is -19.83%.
| Return on Equity (ROE) | -28.87% |
| Return on Assets (ROA) | -19.15% |
| Return on Capital (ROIC) | -19.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.65M |
| Employee Count | 56 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +178.82% in the last 52 weeks. The beta is -0.26, so AKRO's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | +178.82% |
| 50-Day Moving Average | 28.03 |
| 200-Day Moving Average | 24.46 |
| Relative Strength Index (RSI) | 64.21 |
| Average Volume (20 Days) | 465,653 |
Short Selling Information
The latest short interest is 4.72 million, so 6.79% of the outstanding shares have been sold short.
| Short Interest | 4.72M |
| Short Previous Month | 6.77M |
| Short % of Shares Out | 6.79% |
| Short % of Float | 8.57% |
| Short Ratio (days to cover) | 8.67 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -234.18M |
| Pretax Income | -204.18M |
| Net Income | -204.18M |
| EBITDA | -234.17M |
| EBIT | -234.18M |
| Earnings Per Share (EPS) | -$3.40 |
Full Income StatementBalance Sheet
The company has $760.19 million in cash and $35.91 million in debt, giving a net cash position of $812.41 million or $11.70 per share.
| Cash & Cash Equivalents | 760.19M |
| Total Debt | 35.91M |
| Net Cash | 812.41M |
| Net Cash Per Share | $11.70 |
| Equity (Book Value) | 798.07M |
| Book Value Per Share | 11.53 |
| Working Capital | 744.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$190.94 million and capital expenditures -$999,000, giving a free cash flow of -$191.94 million.
| Operating Cash Flow | -190.94M |
| Capital Expenditures | -999,000 |
| Free Cash Flow | -191.94M |
| FCF Per Share | -$2.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |